Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis).

Probert CS, Sebastian S, Gaya DR, Hamlin PJ, Gillespie G, Rose A, Tate H, Wheeler C, Irving PM.

BMJ Open Gastroenterol. 2018 Jul 7;5(1):e000212. doi: 10.1136/bmjgast-2018-000212. eCollection 2018.

2.

Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn's disease (METRIC): a multicentre trial.

Taylor SA, Mallett S, Bhatnagar G, Baldwin-Cleland R, Bloom S, Gupta A, Hamlin PJ, Hart AL, Higginson A, Jacobs I, McCartney S, Miles A, Murray CD, Plumb AA, Pollok RC, Punwani S, Quinn L, Rodriguez-Justo M, Shabir Z, Slater A, Tolan D, Travis S, Windsor A, Wylie P, Zealley I, Halligan S; METRIC study investigators.

Lancet Gastroenterol Hepatol. 2018 Jun 15. pii: S2468-1253(18)30161-4. doi: 10.1016/S2468-1253(18)30161-4. [Epub ahead of print]

3.

Outcomes of Relapsed and Refractory Primary Mediastinal (Thymic) Large B-cell Lymphoma Treated with Second-line Therapy and Intent to Transplant.

Vardhana S, Hamlin PA, Yang J, Zelenetz A, Sauter CS, Matasar MJ, Ni A, Yahalom J, Moskowitz CH.

Biol Blood Marrow Transplant. 2018 Jun 14. pii: S1083-8791(18)30321-5. doi: 10.1016/j.bbmt.2018.06.009. [Epub ahead of print]

PMID:
29909154
4.

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.

Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A.

Blood Cancer J. 2018 Jun 12;8(6):60. doi: 10.1038/s41408-018-0089-0.

5.

Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.

Ratnakumaran R, To N, Gracie DJ, Selinger CP, O'Connor A, Clark T, Carey N, Leigh K, Bourner L, Ford AC, Hamlin PJ.

Scand J Gastroenterol. 2018 Jun;53(6):700-707. doi: 10.1080/00365521.2018.1464203. Epub 2018 Apr 24.

PMID:
29687730
6.

Longitudinal impact of IBS-type symptoms on disease activity, healthcare utilization, psychological health, and quality of life in inflammatory bowel disease.

Gracie DJ, Hamlin PJ, Ford AC.

Am J Gastroenterol. 2018 May;113(5):702-712. doi: 10.1038/s41395-018-0021-z. Epub 2018 Feb 16.

PMID:
29453384
7.

Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin.

Derwa Y, Williams CJM, Sood R, Mumtaz S, Bholah MH, Selinger CP, Hamlin PJ, Ford AC, Gracie DJ.

Therap Adv Gastroenterol. 2018 Jan 18;11:1756283X17744739. doi: 10.1177/1756283X17744739. eCollection 2018.

8.

Bi-directionality of Brain-Gut Interactions in Patients With Inflammatory Bowel Disease.

Gracie DJ, Guthrie EA, Hamlin PJ, Ford AC.

Gastroenterology. 2018 May;154(6):1635-1646.e3. doi: 10.1053/j.gastro.2018.01.027. Epub 2018 Jan 31.

PMID:
29366841
9.

Fatigue in Inflammatory Bowel Disease Reflects Mood and Symptom-Reporting Behavior Rather Than Biochemical Activity or Anemia.

Ratnakumaran R, Warren L, Gracie DJ, Sagar RC, Hamlin PJ, O'Connor A, Ford AC.

Clin Gastroenterol Hepatol. 2018 Jul;16(7):1165-1167. doi: 10.1016/j.cgh.2017.11.030. Epub 2017 Nov 21. No abstract available.

PMID:
29174713
10.

Infliximab Therapeutic Drug Monitoring Changes Clinical Decisions in a Virtual Biologics Clinic for Inflammatory Bowel Disease.

Selinger CP, Lenti MV, Clark T, Rafferty H, Gracie D, Ford AC, OʼConnor A, Ahmad T, Hamlin PJ.

Inflamm Bowel Dis. 2017 Dec;23(12):2083-2088. doi: 10.1097/MIB.0000000000001258.

PMID:
29140939
11.

Development of a Geriatric Service in a Cancer Center: Lessons Learned.

Korc-Grodzicki B, Tew W, Hurria A, Yulico H, Lichtman S, Hamlin P, Bosl G.

J Oncol Pract. 2017 Feb;13(2):107-112. doi: 10.1200/JOP.2016.017590. No abstract available.

12.

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma.

Moskowitz AJ, Schöder H, Gavane S, Thoren KL, Fleisher M, Yahalom J, McCall SJ, Cadzin BR, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz SM, Kumar A, Matasar M, Ni A, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Straus D, Younes A, Zelenetz AD, Moskowitz CH.

Blood. 2017 Nov 16;130(20):2196-2203. doi: 10.1182/blood-2017-06-788877. Epub 2017 Sep 5.

PMID:
28874350
13.

Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis.

O'Connor A, Hamlin PJ, Taylor J, Selinger C, Scott N, Ford AC.

Frontline Gastroenterol. 2017 Jul;8(3):203-209. doi: 10.1136/flgastro-2016-100749. Epub 2016 Dec 1.

14.

Editorial: probiotics in inflammatory bowel disease-wrong organisms, wrong disease, or flawed concepts? Authors' reply.

Gracie DJ, Derwa Y, Hamlin PJ, Ford AC.

Aliment Pharmacol Ther. 2017 Sep;46(6):633-634. doi: 10.1111/apt.14237. No abstract available.

PMID:
28805328
15.

Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.

Dang NH, Ogura M, Castaigne S, Fayad LE, Jerkeman M, Radford J, Pezzutto A, Bondarenko I, Stewart DA, Shnaidman M, Sullivan S, Vandendries E, Tobinai K, Ramchandren R, Hamlin PA, Giné E, Ando K.

Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14820. [Epub ahead of print] No abstract available.

PMID:
28677896
16.

Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease.

Derwa Y, Gracie DJ, Hamlin PJ, Ford AC.

Aliment Pharmacol Ther. 2017 Aug;46(4):389-400. doi: 10.1111/apt.14203. Epub 2017 Jun 27. Review.

PMID:
28653751
17.

Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.

Grommes C, Pastore A, Palaskas N, Tang SS, Campos C, Schartz D, Codega P, Nichol D, Clark O, Hsieh WY, Rohle D, Rosenblum M, Viale A, Tabar VS, Brennan CW, Gavrilovic IT, Kaley TJ, Nolan CP, Omuro A, Pentsova E, Thomas AA, Tsyvkin E, Noy A, Palomba ML, Hamlin P, Sauter CS, Moskowitz CH, Wolfe J, Dogan A, Won M, Glass J, Peak S, Lallana EC, Hatzoglou V, Reiner AS, Gutin PH, Huse JT, Panageas KS, Graeber TG, Schultz N, DeAngelis LM, Mellinghoff IK.

Cancer Discov. 2017 Sep;7(9):1018-1029. doi: 10.1158/2159-8290.CD-17-0613. Epub 2017 Jun 15.

PMID:
28619981
18.

Reply.

Gracie DJ, Williams CJM, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC.

Clin Gastroenterol Hepatol. 2017 Aug;15(8):1315-1316. doi: 10.1016/j.cgh.2017.04.035. Epub 2017 May 4. No abstract available.

PMID:
28479498
19.

Effect of psychological therapy on disease activity, psychological comorbidity, and quality of life in inflammatory bowel disease: a systematic review and meta-analysis.

Gracie DJ, Irvine AJ, Sood R, Mikocka-Walus A, Hamlin PJ, Ford AC.

Lancet Gastroenterol Hepatol. 2017 Mar;2(3):189-199. doi: 10.1016/S2468-1253(16)30206-0. Epub 2017 Jan 18.

PMID:
28404134
20.

Nuances in the Management of Aggressive Lymphomas.

Hamlin PA, Wisniewski M.

J Adv Pract Oncol. 2017 Apr;8(3):279-284. Epub 2017 Apr 1. Review.

21.

The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF.

Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17.

22.

The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease.

Selinger CP, Carbery I, Warren V, Rehman AF, Williams CJ, Mumtaz S, Bholah H, Sood R, Gracie DJ, Hamlin PJ, Ford AC.

Aliment Pharmacol Ther. 2017 Jan;45(1):63-74. doi: 10.1111/apt.13831. Epub 2016 Oct 25.

23.

Response to Levenstein and Prantera.

Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC.

Am J Gastroenterol. 2016 Oct;111(10):1499. doi: 10.1038/ajg.2016.322. No abstract available.

PMID:
27694869
24.

Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma.

Kumar A, Casulo C, Yahalom J, Schöder H, Barr PM, Caron P, Chiu A, Constine LS, Drullinsky P, Friedberg JW, Gerecitano JF, Hamilton A, Hamlin PA, Horwitz SM, Jacob AG, Matasar MJ, McArthur GN, McCall SJ, Moskowitz AJ, Noy A, Palomba ML, Portlock CS, Straus DJ, VanderEls N, Verwys SL, Yang J, Younes A, Zelenetz AD, Zhang Z, Moskowitz CH.

Blood. 2016 Sep 15;128(11):1458-64. doi: 10.1182/blood-2016-03-703470. Epub 2016 Jul 25.

25.

Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma.

Hamlin PA.

Lancet Oncol. 2016 Aug;17(8):1023-1025. doi: 10.1016/S1470-2045(16)30157-7. Epub 2016 Jun 23. No abstract available.

PMID:
27345637
26.

Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.

Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC.

Clin Gastroenterol Hepatol. 2017 Mar;15(3):376-384.e5. doi: 10.1016/j.cgh.2016.05.012. Epub 2016 May 14.

PMID:
27189912
27.

Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.

Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1543-1551. doi: 10.1016/j.bbmt.2016.04.019. Epub 2016 Apr 27. Review.

28.

Central nervous system involvement in T-cell lymphoma: A single center experience.

Gurion R, Mehta N, Migliacci JC, Zelenetz A, Moskowitz A, Lunning M, Moskowitz C, Hamlin P, Horwitz S.

Acta Oncol. 2016 May;55(5):561-6. doi: 10.3109/0284186X.2015.1118656. Epub 2016 Apr 4.

29.

Poor Correlation Between Clinical Disease Activity and Mucosal Inflammation, and the Role of Psychological Comorbidity, in Inflammatory Bowel Disease.

Gracie DJ, Williams CJ, Sood R, Mumtaz S, Bholah MH, Hamlin PJ, Ford AC.

Am J Gastroenterol. 2016 Apr;111(4):541-51. doi: 10.1038/ajg.2016.59. Epub 2016 Mar 22.

PMID:
27002800
30.

A Positive Prospective Trial of Antibiotic Therapy in Advanced Stage, Non-Bulky Indolent Lymphoma.

Portlock CS, Hamlin PA, Gerecitano JF, Noy A, Palomba ML, Walkley J, Corcoran S, Migliacci J, Schoder H, Papanicolaou G, Markowitz AJ.

Tumor Microenviron Ther. 2015 Feb;2(1):14-18. Epub 2015 Feb 18.

31.

Prospective Study of 3'-Deoxy-3'-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma.

Schöder H, Zelenetz AD, Hamlin P, Gavane S, Horwitz S, Matasar M, Moskowitz A, Noy A, Palomba L, Portlock C, Straus D, Grewal R, Migliacci JC, Larson SM, Moskowitz CH.

J Nucl Med. 2016 May;57(5):728-34. doi: 10.2967/jnumed.115.166769. Epub 2015 Dec 30.

32.

High-Dose Chemotherapy and Autologous Stem Cell Transplant in Older Patients with Lymphoma.

Lahoud OB, Sauter CS, Hamlin PA, Dahi PB.

Curr Oncol Rep. 2015 Sep;17(9):42. doi: 10.1007/s11912-015-0465-x. Review.

33.

A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma.

Wagner-Johnston ND, Goy A, Rodriguez MA, Ehmann WC, Hamlin PA, Radford J, Thieblemont C, Suh C, Sweetenham J, Huang Y, Sullivan ST, Vandendries ER, Gisselbrecht C.

Leuk Lymphoma. 2015;56(10):2863-9. doi: 10.3109/10428194.2015.1017821. Epub 2015 Mar 29.

PMID:
25707288
34.

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

Moskowitz AJ, Schöder H, Yahalom J, McCall SJ, Fox SY, Gerecitano J, Grewal R, Hamlin PA, Horwitz S, Kobos R, Kumar A, Matasar M, Noy A, Palomba ML, Perales MA, Portlock CS, Sauter C, Shukla N, Steinherz P, Straus D, Trippett T, Younes A, Zelenetz A, Moskowitz CH.

Lancet Oncol. 2015 Mar;16(3):284-92. doi: 10.1016/S1470-2045(15)70013-6. Epub 2015 Feb 13.

PMID:
25683846
35.

Approach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentary.

Morrison VA, Hamlin P, Soubeyran P, Stauder R, Wadhwa P, Aapro M, Lichtman SM; International Society of Geriatric Oncology.

Ann Oncol. 2015 Jun;26(6):1058-68. doi: 10.1093/annonc/mdv018. Epub 2015 Jan 29. Review.

PMID:
25635006
36.

Long-term efficacy and safety of azathioprine in ulcerative colitis.

Sood R, Ansari S, Clark T, Hamlin PJ, Ford AC.

J Crohns Colitis. 2015 Feb;9(2):191-7.

PMID:
25518053
37.

Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper.

Morrison VA, Hamlin P, Soubeyran P, Stauder R, Wadhwa P, Aapro M, Lichtman S.

J Geriatr Oncol. 2015 Mar;6(2):141-52. doi: 10.1016/j.jgo.2014.11.004. Epub 2014 Dec 7. Review.

PMID:
25491101
38.

Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.

Hamlin PA, Satram-Hoang S, Reyes C, Hoang KQ, Guduru SR, Skettino S.

Oncologist. 2014 Dec;19(12):1249-57. doi: 10.1634/theoncologist.2014-0113. Epub 2014 Oct 23.

39.

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation.

Straus DJ, Hamlin PA, Matasar MJ, Lia Palomba M, Drullinsky PR, Zelenetz AD, Gerecitano JF, Noy A, Hamilton AM, Elstrom R, Wegner B, Wortman K, Cella D.

Br J Haematol. 2015 Mar;168(5):663-70. doi: 10.1111/bjh.13195. Epub 2014 Oct 15.

PMID:
25316653
40.

Outcome of elective withdrawal of anti-tumour necrosis factor-α therapy in patients with Crohn's disease in established remission.

Brooks AJ, Sebastian S, Cross SS, Robinson K, Warren L, Wright A, Marsh AM, Tsai H, Majeed F, McAlindon ME, Preston C, Hamlin PJ, Lobo AJ.

J Crohns Colitis. 2017 Dec 4;11(12):1456-1462. doi: 10.1016/j.crohns.2014.09.007.

PMID:
25311864
41.

Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.

Dahi PB, Tamari R, Devlin SM, Maloy M, Bhatt V, Scordo M, Goldberg J, Zelenetz AD, Hamlin PA, Matasar MJ, Maragulia J, Giralt SA, Perales MA, Moskowitz CH, Sauter CS.

Biol Blood Marrow Transplant. 2014 Dec;20(12):2004-9. doi: 10.1016/j.bbmt.2014.08.019. Epub 2014 Aug 28.

42.

Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma.

Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, de Vos S, Hamlin PA, Kim SK, Whiting NC, Gartner EM, Zhao B, Thompson JA.

Invest New Drugs. 2014 Dec;32(6):1246-57. doi: 10.1007/s10637-014-0151-0. Epub 2014 Aug 22.

PMID:
25142258
43.

Personalizing therapy for older adults with lymphoid malignancies: options and obstacles.

Wildes TM, Goede V, Hamlin P.

Am Soc Clin Oncol Educ Book. 2014:e240-8. doi: 10.14694/EdBook_AM.2014.34.e240. Review.

44.

Evolving treatment paradigms for primary mediastinal diffuse large B-cell lymphoma.

Hamlin PA.

J Clin Oncol. 2014 Jun 10;32(17):1751-3. doi: 10.1200/JCO.2014.55.2810. Epub 2014 May 5. No abstract available.

PMID:
24799491
45.

Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.

Gandhi MD, Evens AM, Fenske TS, Hamlin P, Coiffier B, Engert A, Moskowitz AJ, Ghosh N, Petrich AM, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio SM, Raisch DW, West DP, Gordon LI, Winter JN.

Blood. 2014 May 1;123(18):2895-7. doi: 10.1182/blood-2014-03-561878. No abstract available.

46.

Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease.

Choi GK, Collins SD, Greer DP, Warren L, Dowson G, Clark T, Hamlin PJ, Ford AC.

J Crohns Colitis. 2014 May;8(5):375-83. doi: 10.1016/j.crohns.2013.09.017. Epub 2013 Oct 12.

PMID:
24129316
47.

Commentary: salvage medical therapy for acute severe colitis - ciclosporin or infliximab?

Sprakes MB, Hamlin PJ.

Aliment Pharmacol Ther. 2013 Oct;38(8):988. doi: 10.1111/apt.12436. No abstract available.

48.

A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission.

Mehta N, Maragulia JC, Moskowitz A, Hamlin PA, Lunning MA, Moskowitz CH, Zelenetz A, Matasar MJ, Sauter C, Goldberg J, Horwitz SM.

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):664-70. doi: 10.1016/j.clml.2013.07.005. Epub 2013 Sep 11.

PMID:
24035712
49.

Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience.

Halpin SJ, Hamlin PJ, Greer DP, Warren L, Ford AC.

World J Gastroenterol. 2013 Feb 21;19(7):1091-7. doi: 10.3748/wjg.v19.i7.1091.

50.

Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma.

Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, Noy A, Palomba ML, Portlock CS, Straus DJ, Graustein T, Zelenetz AD, Moskowitz CH.

J Clin Oncol. 2013 Feb 1;31(4):456-60. doi: 10.1200/JCO.2012.45.3308. Epub 2012 Dec 17.

Supplemental Content

Loading ...
Support Center